Outlier in fully replicate BE study [Outliers]

posted by Loky do – Egypt, 2021-06-16 02:49 (1309 d 11:31 ago) – Posting: # 22414
Views: 7,565

Dear colleagues,

During bioanalysis of a fully replicate BE study for drug known to has a potential for back conversion (clopidogrel), one volunteer shows drug concentrations below LLOQ in 3 phases and only one phase (Reference product) shows very low drug concentration, no probability of not swallowing the tablets (mouth check was assured) what could be the reason of this results :confused:? Knowing that the ISR results for the study is accepted?
Thanks in advance

Complete thread:

UA Flag
Activity
 Admin contact
23,362 posts in 4,906 threads, 1,678 registered users;
121 visitors (0 registered, 121 guests [including 8 identified bots]).
Forum time: 13:21 CET (Europe/Vienna)

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5